These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 31710632)

  • 1. How to design a dose-finding study on combined agents: Choice of design and development of R functions.
    Ezzalfani M
    PLoS One; 2019; 14(11):e0224940. PubMed ID: 31710632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRM2DIM: A SAS macro for implementing the dual-agent Bayesian continual reassessment method.
    Bayar MA; Ivanova A; Le Teuff G
    Comput Methods Programs Biomed; 2019 Jul; 176():211-223. PubMed ID: 31200907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Competing designs for drug combination in phase I dose-finding clinical trials.
    Riviere MK; Dubois F; Zohar S
    Stat Med; 2015 Jan; 34(1):1-12. PubMed ID: 24464821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
    Abbas R; Rossoni C; Jaki T; Paoletti X; Mozgunov P
    Clin Trials; 2020 Oct; 17(5):522-534. PubMed ID: 32631095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond the 3+3 method: expanded algorithms for dose- escalation in Phase I oncology trials of two agents.
    Braun TM; Alonzo TA
    Clin Trials; 2011 Jun; 8(3):247-59. PubMed ID: 21730075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering.
    Guo B; Li Y
    Stat Med; 2015 Feb; 34(5):859-75. PubMed ID: 25413162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.
    Lin R; Yin G
    Stat Med; 2017 Nov; 36(26):4106-4120. PubMed ID: 28786138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Bayesian adaptive Phase I-II clinical trial for evaluating efficacy and toxicity with delayed outcomes.
    Koopmeiners JS; Modiano J
    Clin Trials; 2014 Feb; 11(1):38-48. PubMed ID: 24082004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II adaptive design for drug combination oncology trials.
    Wages NA; Conaway MR
    Stat Med; 2014 May; 33(12):1990-2003. PubMed ID: 24470329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Revisiting isotonic phase I design in the era of model-assisted dose-finding.
    Wages NA; Conaway MR
    Clin Trials; 2018 Oct; 15(5):524-529. PubMed ID: 30101616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial design for drug combinations with Bayesian model averaging.
    Jin IH; Huo L; Yin G; Yuan Y
    Pharm Stat; 2015; 14(2):108-19. PubMed ID: 25641851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Keyboard design for phase I drug-combination trials.
    Pan H; Lin R; Zhou Y; Yuan Y
    Contemp Clin Trials; 2020 May; 92():105972. PubMed ID: 32151751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian adaptive linearization method for phase I drug combination trials with dimension reduction.
    Pan H; Cheng C; Yuan Y
    Pharm Stat; 2020 Sep; 19(5):561-582. PubMed ID: 32248647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A practical Bayesian design to identify the maximum tolerated dose contour for drug combination trials.
    Zhang L; Yuan Y
    Stat Med; 2016 Nov; 35(27):4924-4936. PubMed ID: 27580928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design considerations for phase I/II dose finding clinical trials in Immuno-oncology and cell therapy.
    Liu R; Lin J; Li P
    Contemp Clin Trials; 2020 Sep; 96():106083. PubMed ID: 32659438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic ordering design for dose finding in drug-combination trials.
    Zhang T; Yang Z; Yin G
    Pharm Stat; 2021 Mar; 20(2):348-361. PubMed ID: 33236520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flexible use of copula-type model for dose-finding in drug combination clinical trials.
    Hashizume K; Tshuchida J; Sozu T
    Biometrics; 2022 Dec; 78(4):1651-1661. PubMed ID: 34181760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An adaptive model switching approach for phase I dose-finding trials.
    Daimon T; Zohar S
    Pharm Stat; 2013; 12(4):225-32. PubMed ID: 23801550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A clinical phase I dose-finding design with adaptive shrinking boundaries for drug combination trials.
    Li Z; Xu Z; Zhang A; Qi G; Li Z
    BMC Med Res Methodol; 2023 Mar; 23(1):57. PubMed ID: 36864387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adapting isotonic dose-finding to a dynamic set of drug combinations with application to a phase I leukemia trial.
    Wages NA; Reed DR; Keng MK; Conaway MR; Petroni GR
    Clin Trials; 2021 Jun; 18(3):314-323. PubMed ID: 33426919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.